LON:AMYT Amryt Pharma (AMYT) Share Price, News & Analysis GBX 143 -19.00 (-11.73%) (As of 01/10/2022) Add Compare Share Share Today's Range 143▼ 15550-Day Range 143▼ 14352-Week Range 135▼ 230Volume90,726 shsAverage Volume469,552 shsMarket Capitalization£457.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Amryt Pharma alerts: Email Address Ad True Market InsidersAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Amryt Pharma Stock (LON:AMYT)Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.Read More AMYT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMYT Stock News HeadlinesJuly 26 at 5:32 AM | americanbankingnews.comAmryt Pharma (LON:AMYT) Stock Crosses Below 50 Day Moving Average of $143.00March 22, 2023 | finance.yahoo.comAmryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi FarmaceuticiJuly 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.January 16, 2023 | msn.comChiesi Farmaceutici S.p.A. to acquire Amryt PharmaJanuary 10, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Amryt Pharma Plc BuyoutJanuary 9, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMYT, CINC, ALBOJanuary 9, 2023 | technews.tmcnet.comAMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to ShareholdersJanuary 8, 2023 | news.yahoo.comItaly's Chiesi Farmaceutici to buy Amryt Pharma in a $1.48 billion dealJuly 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.January 8, 2023 | au.finance.yahoo.comChiesi Farmaceutici S.p.A. to Acquire Amryt Pharma PlcDecember 5, 2022 | ca.finance.yahoo.comEuropean Commission approves Mycapssa® for the treatment of AcromegalyOctober 31, 2022 | nz.finance.yahoo.comAmryt Supports Acromegaly Awareness Day 2022October 17, 2022 | finance.yahoo.comAmryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)October 15, 2022 | seekingalpha.comAMYT Amryt Pharma plcAugust 6, 2022 | seekingalpha.comAmryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call TranscriptAugust 4, 2022 | finance.yahoo.comAmryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue EstimatesJuly 30, 2022 | morningstar.comAmryt Pharma PLC ADR Stock Quote AMYTJune 27, 2022 | seekingalpha.comAmryt Pharma appoints Dr Tracy Cunningham as Chief Medical OfficerSee More Headlines Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolLON:AMYT Previous SymbolLON:FAST CUSIPN/A CIKN/A Webwww.amrytpharma.com Phone+44-20-34155730FaxN/AEmployees290Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio66.05 Current Ratio1.80 Quick Ratio1.14 Sales & Book Value Annual Sales£210.24 million Price / Sales2.17 Cash FlowGBX 38.90 per share Price / Cash Flow3.68 Book ValueGBX 96.60 per share Price / Book1.48Miscellaneous Outstanding Shares319,657,000Free FloatN/AMarket Cap£457.11 million OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Joseph A. Wiley (Age 50)CEO & Director Comp: $1.72MMr. Rory P. Nealon (Age 53)CFO, COO & Company Sec. Comp: $931kMs. Elizabeth Varki Jobes J.D. (Age 54)Sr. VP & Global Chief Compliance Officer Mr. John McEvoyGen. CounselMr. Stephen JoyceVP of Global MarketingMs. Julie EastwoodHead of HRMs. Derval O'CarrollHead of Regulatory AffairsMr. Gerry GilliganHead of Manufacturing Supply ChainDr. Mark Sumeray (Age 55)Chief Medical Officer Mr. David AllmondChief Commercial OfficerMore ExecutivesKey CompetitorsGraingerLON:GRISilence TherapeuticsLON:SLNGlobal PortsLON:GPHPharos EnergyLON:PHARMarks Electrical GroupLON:MRKView All Competitors AMYT Stock Analysis - Frequently Asked Questions How have AMYT shares performed this year? Amryt Pharma's stock was trading at GBX 143 at the beginning of 2024. Since then, AMYT stock has increased by 0.0% and is now trading at GBX 143. View the best growth stocks for 2024 here. How do I buy shares of Amryt Pharma? Shares of AMYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Amryt Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amryt Pharma investors own include The Parkmead Group (PMG), Himax Technologies (HIMX), Atalaya Mining (ATYM), Concepta PLC (CPT.L) (CPT), Faroe Petroleum (FPM), Vectura Group (VEC) and Xcite Energy (XEL). This page (LON:AMYT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amryt Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMYT Stock Alerts